Understanding the AllTrials Campaign: Its Progress, Impact, and Ongoing Challenges

What Is the AllTrials Campaign and Why Was It Launched?

Launched in 2013, the AllTrials campaign became a defining movement in the fight for full transparency in clinical research. Led by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, AllTrials raised global awareness of the problem of hidden and unreported clinical trial results—particularly those with negative or inconclusive outcomes.

The core slogan, “All Trials Registered. All Results Reported.”, crystallized the campaign’s demands for better transparency, improved access to data, and global policy reform. The concern was not academic—non-publication of trial data leads to evidence gaps in medicine, flawed systematic reviews, biased clinical guidelines, and ultimately, suboptimal patient care.

Founding Members and Their Vision

The campaign’s founding members were influential: Cochrane brought its evidence synthesis legacy; BMJ added editorial authority; and Ben Goldacre, through Bad Pharma, revealed pharmaceutical industry shortcomings. The mission was clear:

• Ensure that all clinical trials are registered in a public database before patient recruitment begins
• Mandate reporting of all trial results, regardless of outcomes
• Encourage retrospective registration and disclosure of past trials
• Push for enforceable legislation across jurisdictions

The campaign filled a void left by slow-moving policy, calling out both public institutions and private sponsors for failing to disclose complete data sets.

Milestones Achieved by the Campaign

The AllTrials campaign has achieved significant global visibility and policy impact over the last decade:

• Over 750 organizations signed the AllTrials petition, including medical societies, research funders, and ethics boards
• EMA’s Policy 0070 and EU Clinical Trial Regulation (EU CTR 536/2014) emerged around the same period, supporting proactive disclosure
• Tools like the FDAAA TrialsTracker were developed to monitor sponsor compliance
• Major journals like The Lancet and BMJ made trial registration a prerequisite for publication

Some companies, such as GSK and Johnson & Johnson, pledged to publish trial results proactively. The UK Health Research Authority (HRA) enforced reporting of all trials approved after 2018.

Public Engagement and Open Data Advocacy

Beyond the policy sphere, AllTrials galvanized public support with a petition that received more than 90,000 signatures globally. This grassroots activism sent a clear message to sponsors and regulators: society demands accountability.

The campaign also aligned itself with broader open data and open science movements, promoting reusable datasets and transparency across disciplines. Many academic institutions were prompted to retrospectively register trials and update their result disclosure practices to avoid reputational harm.

Academic Impact and Journal Response

The campaign influenced academic policy significantly. The International Committee of Medical Journal Editors (ICMJE) reinforced its position on trial registration as a publication condition. Guidelines like CONSORT were updated to emphasize complete and timely results disclosure. Systematic reviews began flagging risk of bias due to missing data more aggressively.

Studies also started evaluating transparency metrics. For instance, a PLOS Medicine analysis in 2020 showed that trial reporting among top-tier research institutions improved post-AllTrials, though gaps remain in smaller, investigator-initiated studies.

Challenges and Barriers to Full Compliance

Despite its success, the campaign faces key barriers:

• Enforcement is weak – Legal penalties for non-compliance remain rare outside the U.S.
• Legacy data is inaccessible – Pre-2007 trials remain largely unpublished, and efforts to retrieve those datasets are underfunded
• Resource gaps at small sponsors – Investigator-led trials often lack administrative support for registration and reporting
• Lack of harmonization – Registries like ClinicalTrials.gov, EU CTR, and ICTRP differ in their formats, making global compliance complex

Efforts to address these gaps continue, with transparency advocates lobbying for tougher laws and better sponsor accountability scorecards. Projects like ClinicalStudies.in are helping train institutions in practical compliance tools and global registry management.

Ongoing Monitoring and Compliance Tools

Transparency monitoring has evolved with technology. Platforms like TranspariMED, EU TrialsTracker, and WHO’s ICTRP now offer dashboards to benchmark disclosure by sponsor, country, and funder. Some regulators have started naming and shaming non-compliant institutions, creating reputational incentives for transparency.

Meanwhile, institutions like PharmaValidation.in are developing SOPs and compliance templates for consistent reporting, reducing administrative burden on research sponsors.

Conclusion: A Campaign That Reshaped Clinical Research Norms

The AllTrials campaign permanently changed how clinical research is conducted, reviewed, and disseminated. From patient advocacy to policy reform and journal mandates, the campaign has made a lasting mark.

However, transparency is a continuous journey. The next decade will require stricter enforcement, smarter registries, and full data accessibility—especially in underrepresented regions. The AllTrials legacy remains a blueprint for future movements fighting for ethical, evidence-based science in public health.

To explore global guidelines aligned with AllTrials values, visit the ICH Quality Guidelines and related transparency publications from PharmaRegulatory.in.

Ensuring Ethical Publication of Clinical Trials Through GPP Guidelines

Introduction to GPP: Why Ethical Publication Matters

Clinical trial publications shape medical guidelines, regulatory decisions, and patient care. Ethical lapses such as ghostwriting, selective reporting, or sponsor bias can undermine the scientific integrity of published results. To address these concerns, the International Society for Medical Publication Professionals (ISMPP) developed the Good Publication Practice (GPP) guidelines, currently in its third version (GPP3).

These guidelines aim to promote transparency, responsible authorship, and ethical sponsor engagement in the publication of clinical trial data. GPP applies to pharmaceutical companies, contract research organizations (CROs), academic collaborators, and medical writers involved in the publication planning and dissemination process.

Core Principles of GPP3

GPP3 outlines the ethical standards and operational expectations for preparing and publishing trial-related manuscripts. Core principles include:

• Transparency: Disclose sponsor involvement, funding sources, and data access rights clearly.
• Accountability: Ensure all listed authors meet the ICMJE authorship criteria.
• Accuracy: Report trial results honestly, without bias, spin, or data manipulation.
• Timeliness: Publish results in a timely manner consistent with regulatory disclosure timelines.
• Respect for contributors: Acknowledge the roles of statisticians, writers, and investigators.

These standards align with ICMJE’s Uniform Requirements and complement regulatory requirements from FDA, EMA, and WHO registries.

Authorship Ethics: Avoiding Misconduct

One of the most critical elements in ethical publishing is defining who qualifies as an author. According to both GPP and ICMJE guidelines, authors must meet all of the following criteria:

• Substantial contribution to study design, data analysis, or interpretation
• Drafting or revising the article critically for intellectual content
• Approval of the final version for publication
• Accountability for the accuracy and integrity of the published content

GPP3 strongly discourages ghostwriting—where individuals contribute without acknowledgment—or guest authorship—where individuals are credited without meaningful contribution. Both practices are considered publication misconduct.

Managing Sponsor Involvement and Independence

Sponsors often fund and manage trials, but their role in publication must be disclosed and regulated. Ethical sponsor practices include:

• Allowing authors full access to data or summary-level analyses
• Refraining from controlling the publication’s message or conclusions
• Disclosing conflicts of interest (COIs) related to employment, funding, or stock ownership
• Ensuring transparency about editorial assistance from medical writers

Example: In a multi-site trial on a novel anticoagulant, the sponsor may support writing through an external medical communication agency. However, all authors should approve the content, and the writer’s name and funding source must be disclosed.

Publication Planning and Documentation

Ethical publication also involves organized planning. GPP3 recommends sponsors and authors collaboratively develop a publication plan that includes:

• A publication timeline linked to trial milestones (e.g., database lock, CSR finalization)
• A list of planned abstracts, posters, and manuscripts
• Defined roles and responsibilities for each author and contributor
• A process for conflict resolution and content approval

Publication plans help avoid publication bias by documenting the intent to publish all prespecified outcomes, regardless of result significance. Many sponsors now maintain internal SOPs to govern these workflows.

External Guidelines Complementing GPP

GPP guidelines work in tandem with several other international frameworks:

• EU CTR: Requires summary results and layperson summaries within 12 months of trial completion
• FDAAA 801: Mandates results reporting on ClinicalTrials.gov
• ICMJE: Sets criteria for authorship and trial registration
• WHO ICTRP: Advocates for global result disclosure standards

GPP-compliant sponsors should ensure their practices do not contradict these overlapping obligations.

Role of Medical Writers and Review Committees

Medical writers play an integral role in transforming complex trial data into clear, accurate, and ethical publications. GPP encourages acknowledgment of their work and insists on:

• Documentation of writing contributions in the manuscript or submission form
• Verification that writers had no role in data manipulation or outcome shaping
• Confirmation that writers received direction from authors, not solely from the sponsor

Meanwhile, publication review committees (PRCs) at many organizations ensure that all manuscripts meet internal quality standards and GPP principles before journal submission.

Common Violations and Their Consequences

GPP violations can lead to severe reputational and regulatory consequences. Common violations include:

• Failing to disclose sponsor involvement
• Publishing only favorable outcomes (publication bias)
• Suppressing trial data or delaying negative result publication
• Adding honorary or ghost authors
• Not declaring writer contributions or financial support

Example: In a 2020 audit of 75 industry-sponsored trials published in top journals, over 20% failed to disclose medical writing support—despite involvement. Journals like The Lancet and BMJ have since tightened disclosure policies.

Conclusion: Making GPP a Standard Practice

The GPP guidelines represent a foundational framework for ethical trial result publication. Implementing GPP practices not only ensures compliance but fosters trust among peers, regulators, patients, and the public. Sponsors, CROs, and academic institutions should integrate GPP into their publication SOPs, training, and governance systems.

As clinical trial disclosure becomes increasingly regulated, ethical publication isn’t just a best practice—it’s a moral, scientific, and legal imperative. Upholding GPP principles safeguards the value of medical research and protects the patients whose participation makes it possible.

How to Ethically and Effectively Publish Clinical Trial Results in Scientific Journals

Introduction: From Data to Peer-Reviewed Impact

Publishing the results of clinical trials in peer-reviewed journals is a crucial step in the research lifecycle. It transforms raw data into publicly available evidence, informs medical decision-making, and validates the ethical commitment made to trial participants. However, publication involves more than just writing a manuscript—it requires adherence to transparency policies, ethical standards, and scientific rigor.

Today’s regulatory and editorial landscape is stricter than ever. Journals—particularly those aligned with the International Committee of Medical Journal Editors (ICMJE)—now demand prospective registration, full results disclosure, and compliance with reporting standards such as CONSORT. This tutorial explores how clinical trial sponsors and investigators can navigate the publication process successfully and ethically.

Trial Registration and ICMJE Publication Policy

As a prerequisite for publication in major medical journals, trials must be prospectively registered in a publicly accessible registry approved by the WHO ICTRP (e.g., ClinicalTrials.gov, CTRI, ISRCTN). The ICMJE mandates this to prevent selective reporting and publication bias.

Key expectations include:

• Registration before the first participant is enrolled
• Use of a WHO-compliant registry
• Inclusion of the Trial Registration Number (TRN) in the manuscript

Failure to meet these conditions may lead to automatic manuscript rejection, regardless of scientific merit.

Choosing the Right Journal for Publication

Choosing the right target journal affects not only visibility but also the peer-review timeline and acceptance chances. Consider the following criteria:

• Scope alignment: Match the journal’s audience and therapeutic area
• Impact factor and indexing: Ensure indexing in PubMed, Scopus, or Web of Science
• Open access policies: Consider funder mandates for OA publishing
• Disclosure and ethics policies: Review the journal’s stance on registration, data sharing, and conflicts of interest

Top journals like NEJM, The Lancet, BMJ, and JAMA have detailed author guidelines and expect full transparency from submission.

Manuscript Structure: Following CONSORT Guidelines

The CONSORT (Consolidated Standards of Reporting Trials) statement provides a checklist and flow diagram to guide the transparent reporting of randomized controlled trials. Common manuscript sections include:

• Abstract: Structured summary with trial ID
• Introduction: Rationale, objectives, and trial design summary
• Methods: Eligibility criteria, interventions, randomization, blinding
• Results: Participant flow, outcomes, adverse events, statistical analyses
• Discussion: Interpretation, limitations, generalizability, and ethical context

Manuscripts should be concise, evidence-based, and reference all pre-registered outcomes and deviations.

Handling Negative or Inconclusive Results

One of the biggest ethical lapses in trial transparency is failure to publish negative or inconclusive results. However, many journals explicitly encourage such submissions because they:

• Prevent unnecessary duplication of research
• Reduce publication bias
• Support accurate systematic reviews and meta-analyses

Authors should resist the urge to suppress disappointing findings. Instead, contextualize them in the discussion section and focus on scientific learning and future implications.

Addressing Authorship and Conflict of Interest

Authorship must reflect substantial contribution to the conception, design, data analysis, or manuscript drafting. Most journals follow ICMJE authorship criteria:

• Contribution to trial design or data collection
• Drafting or revising the manuscript
• Approval of the final version
• Accountability for content accuracy

Disclosures of financial or personal conflicts of interest are mandatory. Failure to do so can lead to retraction or reputational harm.

Preprint Servers and Early Data Sharing

Increasingly, trial results are shared via preprint servers such as medRxiv or bioRxiv. While these are not peer-reviewed, they allow early access to findings and support open science. However:

• Journals may have policies regarding prior dissemination—always check
• Clearly label the version as a preprint in the manuscript submission
• Avoid media press releases until after peer-review, unless permitted

Preprints are useful for public health emergencies (e.g., COVID-19) or when rapid dissemination is critical.

Best Practices for a Successful Submission

To maximize publication success:

• Include the trial registration number in the title page and abstract
• Cross-check outcomes with registered protocol—explain deviations
• Use reporting checklists (e.g., CONSORT, SPIRIT, STROBE)
• Submit to a journal with a history of publishing similar trials
• Ensure all disclosures and acknowledgments are included

Consider submitting graphical abstracts, plain language summaries, and data availability statements to improve transparency and reach.

Conclusion: Publishing Is a Transparency Milestone

Publishing clinical trial results in peer-reviewed journals is both a scientific obligation and a regulatory requirement. With expectations rising around transparency, ethical authorship, and data accessibility, sponsors must treat publication planning as a core component of trial design.

By following registry policies, reporting standards, and journal requirements, researchers can ensure their findings contribute to the evidence base, respect participant contributions, and stand up to public and scientific scrutiny.